MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, LCTX made $3,681,000 in revenue. -$29,781,000 in net income. Net profit margin of -809.05%.

Income Overview

Revenue
$3,681,000
Net Income
-$29,781,000
Net Profit Margin
-809.05%
EPS
-$0.13
Unit: Dollar
Revenue Breakdown
    • Collaboration Revenues
    • Royalties License And Other Reve...
Revenue Breakdown
    • Other Collaborative Revenue
    • Upfront License Fees
    • Royalties, license and other rev...

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Total revenues
3,681,000 2,765,000 1,502,000 1,906,666.667
Cost of royalties
5,000 39,000 --
Research and development
3,271,000 3,106,000 3,114,000 3,100,333.333
General and administrative
4,191,000 4,560,000 4,857,000 4,587,000
Cost of sales
--36,000 98,666.667
Loss on impairment of intangible asset (note 6 and note 13)
0 14,840,000 --
Total operating expenses
7,467,000 22,545,000 8,007,000 7,786,000
Loss from operations
-3,786,000 -19,780,000 -6,505,000 -5,879,333.333
Interest income, net
366,000 454,000 478,000 560,833.333
Gain (loss) on marketable equity securities, net
6,000 -2,000 -5,000 -666.667
Change in fair value of warrant liability
26,557,000 12,740,000 -2,305,000 -532,000
Foreign currency transaction gain (loss), net
219,000 1,678,000 -231,000 -239,000
Other income (expense), net
0 26,000 -185,000 -167,500
Loss before income taxes
----5,193,666.667
Total other income (expenses)
-25,966,000 -10,584,000 2,362,000 685,666.667
Net loss
-29,752,000 -30,364,000 -4,143,000 -5,193,666.667
Net (income) loss attributable to noncontrolling interest
29,000 100,000 -4,000 -2,000
Net loss attributable to lineage
-29,781,000 -30,464,000 -4,139,000 -5,191,666.667
Basic net loss per share
-0.13 -0.13 -0.02 -0.023
Diluted net loss per share
-0.13 -0.13 -0.02 -0.023
Weighted average number of shares outstanding, basic, total
228,853,000 228,356,000 226,054,000 3,786,000
Weighted average number of shares outstanding, diluted
228,853,000 228,356,000 226,054,000 3,786,000
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to lineage-$29,781,000 Net (income) lossattributable to...$29,000 Net loss-$29,752,000 Royalties License AndOther Revenues$137,000 Collaboration Revenues$3,544,000 Total other income(expenses)-$25,966,000 Loss from operations-$3,786,000 Foreign currencytransaction gain (loss), net$219,000 Gain (loss) onmarketable equity...$6,000 Interest income, net$366,000 Total revenues$3,681,000 Change in fair value ofwarrant liability$26,557,000 Total operatingexpenses$7,467,000 General andadministrative$4,191,000 Research and development$3,271,000 Cost of royalties$5,000

Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics, Inc. (LCTX)